Li X - Search Results

1

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer.

Chen B, Zhang G, Li X, Ren C, Wang Y, Li K, Mok H, Cao L, Wen L, Jia M, Li C, Guo L, Wei G, Lin J, Li Y, Zhang Y, Han-Zhang H, Liu J, Lizaso A, Liao N. Chen B, et al. Among authors: li c, li y, li x, li k. Aging (Albany NY). 2020 Feb 24;12(4):3140-3155. doi: 10.18632/aging.102783. Epub 2020 Feb 24. Aging (Albany NY). 2020. PMID: 32091409 Free PMC article.

2

[A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers].

Liao N, Zhang GC, Li XR, Yao M, Wang K. Liao N, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2009 May;29(5):943-5. Nan Fang Yi Ke Da Xue Xue Bao. 2009. PMID: 19460715 Chinese.

3

[Efficacy and safety assessment of neoadjuvant paclitaxel and trastuzumab in Chinese women with Her-2 positive operable breast cancer].

Liao N, Zhang GC, Li XR, Yao M, Wang K, Zu J. Liao N, et al. Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):544-7. Zhonghua Zhong Liu Za Zhi. 2010. PMID: 21029701 Clinical Trial. Chinese.

4

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

Liao N, Zhang GC, Liu YH, Li XR, Yao M, Xu FP, Li L, Wu YL. Liao N, et al. Pathol Res Pract. 2011 Jan 15;207(1):1-7. doi: 10.1016/j.prp.2010.08.005. Epub 2010 Nov 20. Pathol Res Pract. 2011. PMID: 21095069

5

Pre-treatment hormonal receptor status and Ki67 index predict pathologic complete response to neoadjuvant trastuzumab/taxanes but not disease-free survival in HER2-positive breast cancer patients.

Zhang GC, Qian XK, Guo ZB, Ren CY, Yao M, Li XR, Wang K, Zu J, Liao N. Zhang GC, et al. Med Oncol. 2012 Dec;29(5):3222-31. doi: 10.1007/s12032-012-0242-8. Epub 2012 May 1. Med Oncol. 2012. PMID: 22547076

6

Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience.

Zhang GC, Liao N, Guo ZB, Qian XK, Ren CY, Yao M, Li XR, Wang K, Zu J. Zhang GC, et al. Clin Transl Oncol. 2013 Jan;15(1):79-84. doi: 10.1007/s12094-012-0885-0. Epub 2012 Aug 28. Clin Transl Oncol. 2013. PMID: 22926944

7

Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.

Wang K, Deng QT, Liao N, Zhang GC, Liu YH, Xu FP, Zu J, Li XR, Wu YL. Wang K, et al. Tumour Biol. 2013 Feb;34(1):33-8. doi: 10.1007/s13277-012-0507-z. Epub 2012 Sep 14. Tumour Biol. 2013. PMID: 22976542

8

The lncRNA NEAT1 facilitates cell growth and invasion via the miR-211/HMGA2 axis in breast cancer.

Li X, Wang S, Li Z, Long X, Guo Z, Zhang G, Zu J, Chen Y, Wen L. Li X, et al. Among authors: li z. Int J Biol Macromol. 2017 Dec;105(Pt 1):346-353. doi: 10.1016/j.ijbiomac.2017.07.053. Epub 2017 Jul 16. Int J Biol Macromol. 2017. PMID: 28720546

9

Analysis of Prognostic Factors Affecting the Brain Metastases Free Survival and Survival After Brain Metastases in Breast Cancer.

Xiao W, Li X, Yang A, Chen B, Zheng S, Zhang G, Deng W, Liao N. Xiao W, et al. Among authors: li x. Front Oncol. 2020 Apr 3;10:431. doi: 10.3389/fonc.2020.00431. eCollection 2020. Front Oncol. 2020. PMID: 32309214 Free PMC article.

10

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA.

Li X, Chen X, Wen L, Wang Y, Chen B, Xue Y, Guo L, Liao N. Li X, et al. Thorac Cancer. 2020 Jul;11(7):1861-1868. doi: 10.1111/1759-7714.13467. Epub 2020 May 15. Thorac Cancer. 2020. PMID: 32412177 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179,705 results

Search Page

Filters